About us

Polbionica – innovation biotechnic company.
We develop a 3D bionic pancreas and supply key products for the advancement of 3D bioprinting.

Polbionica is a spin-off from the Foundation of Research and Science Development, which bioprinted the world’s first bionic pancreas with full vasculature in March 2019. Polbionica holds expertise in bioprinting and type 1 diabetes (T1D), and has an extensive collaborative network of experts and Key Opinion Leaders.
Our mission is to introduce 3D bioprinting into clinical practice worldwide. Our vision is a fully functional bionic pancreas as a new gold standard T1D treatment. Our strategy is to bring to market the key building blocks for the bioprinting of a bionic organ: a novel bioreactor ReaserchLine and bioinks’s line TintaBionic and Printiss with unique physiological properties. Polbionica aims to fill the gap between organ shortage and transplantation needs.

The research team has benefited from a €6M STRATEGMED grant from the National Centre for Research and Development in Poland to develop the technology. Our achievements as pioneers of the niche of bionic pancreas received international media coverage. Our efforts were also acknowledged by numerous awards: Golden Leader of Health Care (category Innovative Ideas), Golden Scalpel award for the innovators in Polish Health Care, and “Poster of distinction” and “Best in Congress Poster” from the American Transplant Congress. Our Phase 1 SME instrument application received Seal of Excellence.

Our Quality Policy

Polbionica is a company that grew out of the scientific community. OuPolbionica is a company that grew out of the scientific community. Our goal is to commercialize the results of scientific work and implement bioprinted organs, tissues and biomaterials into the economy, both for clinical needs in transplantology and regenerative medicine, and for pharmaceutical purposes in the process of creating new drugs, or conducting research and development work by scientific centers.

We strive for bioprinted organs, tissues and biomaterials to become a standard used in clinical trials, transplantology and regenerative medicine, as well as in pharmaceuticals during the process of creating new drugs.

The above objectives are achieved through the implemented and constantly improved Quality Management System compliant with ISO 13485 standard. In order to achieve our goals, mission and policy, we also undertake to meet all legal, regulatory and other requirements related to our activities.r goal is to commercialize the results of scientific work and implement bioprinted organs, tissues and biomaterials into the economy, both for clinical needs in transplantology and regenerative medicine, and for pharmaceutical purposes in

What makes us stand out

Innovation

We deal with an innovative field on a global scale.

Pursuing a goal

Our main motivation is the goal we want to achieve.

Experience and passion

Our team consists of experts who are passionate about their work.

Quality

The effects of our work are always of the highest quality.

Partnership

We focus on partnership relations with our clients.

Our team

Polbionica is an interdisciplinary, committed and open to challenges team.

Our team consists of doctors, medical consultants, biotechnologists, engineers and laboratory technicians, but also quality experts, business creators, specialists in… sales and administration. Together, we strive to improve the lives of patients with diabetes.